Lung Cancer Articles

Frontline Pembrolizumab Combo Improves Survival in Phase III NSCLC Trial
Combining pembrolizumab with chemotherapy in the frontline setting improved survival in patients with nonsquamous non–small cell lung cancer.
Bunn Expands on Significance of Atezolizumab/Bevacizumab Regimen in NSCLC
Paul A. Bunn, Jr, MD, discusses the IMpower150 study and other immunotherapy combinations in NSCLC.
Hyperprogression Emerges in a Subset of Patients Treated With Immunotherapy
Results from a recent multicenter, retrospective analysis of 242 patients with advanced non–small cell lung cancer (NSCLC) found that 16% developed hyperprogression during anti–PD-1/PD-L1 treatment.
The FDA has expanded the frontline indication for afatinib to include the treatment of patients with metastatic non–small cell lung cancer whose tumors harbor uncommon EGFR alterations in L861Q, G719X, and/or S768I.
Faster Care for Low-Income Patients: New Lung Cancer Treatment Models Emerge
The effort to improve outcomes of disadvantaged patients involves every aspect of lung cancer care.
Lecia V. Sequist, MD, reflects on the practice-changing osimertinib data, ongoing trials exploring combination regimens, and discusses the potential for immunotherapy in EGFR-positive NSCLC.
Finding the Best Spot for PD-1/PD-L1 Antibodies in Advanced Lung Cancer
Amid rapid-fire developments in non–small cell lung cancer (NSCLC) research, the role of checkpoint immunotherapy continues to mature.
Increasing evidence suggests that immune responses against SCLC cells make immunotherapy a rational approach.
Erminia Massarelli, MD, PhD, discusses the evolving paradigm of ALK-positive non-small cell lung cancer based on recent regulatory decisions and what additional advancements are expected in the year ahead.
Neoadjuvant Immunotherapy Being Investigated in Early-Stage NSCLC
Jae Y. Kim, MD, discusses developments with checkpoint inhibition in patients with resectable NSCLC.
Publication Bottom Border
Border Publication